NO995221L - Sulfonamider for behandling av endotelin-medierte sykdommer - Google Patents

Sulfonamider for behandling av endotelin-medierte sykdommer

Info

Publication number: NO995221L
Authority: NO; Norway
Prior art keywords: sulfonamides; isoxazolyl; formulations; sulfonamide; endothelin
Prior art date: 1997-04-28

Application number

NO995221A

Other languages

English (en)

Norwegian (no)

Other versions

NO995221D0 (no

Inventor

Chengde Wu

Natalie Blok

Timothy Kogan

Karin Keller

Patricia Woodard

Original Assignee

Texas Biotechnology Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-28

Filing date

1999-10-26

Publication date

1999-12-28

1997-04-28 Priority claimed from US08/847,797 external-priority patent/US5783705A/en

1999-10-26 Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp

1999-10-26 Publication of NO995221D0 publication Critical patent/NO995221D0/no

1999-12-28 Publication of NO995221L publication Critical patent/NO995221L/no

Links

229940124530 sulfonamide Drugs 0.000 title abstract 7
150000003456 sulfonamides Chemical class 0.000 title abstract 6
102000002045 Endothelin Human genes 0.000 title abstract 2
108050009340 Endothelin Proteins 0.000 title abstract 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000001404 mediated effect Effects 0.000 title 1
238000009472 formulation Methods 0.000 abstract 3
125000000842 isoxazolyl group Chemical group 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
239000000203 mixture Chemical class 0.000 abstract 3
USZKOIUIZMUMSE-UHFFFAOYSA-N 1h-pyrrole-2-sulfonamide Chemical class NS(=O)(=O)C1=CC=CN1 USZKOIUIZMUMSE-UHFFFAOYSA-N 0.000 abstract 2
229910052783 alkali metal Inorganic materials 0.000 abstract 2
-1 alkali metal salt Chemical class 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
150000001340 alkali metals Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
125000002541 furyl group Chemical group 0.000 abstract 1
230000002209 hydrophobic effect Effects 0.000 abstract 1
239000012074 organic phase Substances 0.000 abstract 1
239000003960 organic solvent Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
239000012266 salt solution Substances 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
159000000000 sodium salts Chemical class 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO995221A 1997-04-28 1999-10-26 Sulfonamider for behandling av endotelin-medierte sykdommer NO995221L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/847,797 US5783705A (en)	1997-04-28	1997-04-28	Process of preparing alkali metal salys of hydrophobic sulfonamides
US08/938,444 US6248767B1 (en)	1997-04-28	1997-09-26	Formulation of sulfonamides for treatment of endothelin-mediated disorders
PCT/US1998/006680 WO1998049162A1 (en)	1997-04-28	1998-04-02	Sulfonamides for treatment of endothelin-mediated disorders

Publications (2)

Publication Number	Publication Date
NO995221D0 NO995221D0 (no)	1999-10-26
NO995221L true NO995221L (no)	1999-12-28

Family

ID=27126732

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO995221A NO995221L (no)	1997-04-28	1999-10-26	Sulfonamider for behandling av endotelin-medierte sykdommer

Country Status (25)

Country	Link
US (3)	US6432994B1 (id)
EP (1)	EP0980369B1 (id)
JP (3)	JP3455233B2 (id)
CN (2)	CN1179961C (id)
AP (1)	AP9901643A0 (id)
AT (1)	ATE292129T1 (id)
AU (1)	AU749167B2 (id)
BR (1)	BR9812258A (id)
CA (2)	CA2496680A1 (id)
CZ (1)	CZ301452B6 (id)
DE (2)	DE69839534D1 (id)
EA (1)	EA003993B1 (id)
EE (1)	EE04156B1 (id)
ES (1)	ES2241133T3 (id)
HU (1)	HU227183B1 (id)
ID (1)	ID25921A (id)
IL (2)	IL156977A (id)
NO (1)	NO995221L (id)
NZ (1)	NZ336898A (id)
OA (1)	OA11167A (id)
PL (1)	PL197843B1 (id)
SG (2)	SG100766A1 (id)
SK (1)	SK143399A3 (id)
TR (3)	TR200202738T2 (id)
WO (1)	WO1998049162A1 (id)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5962490A (en) *	1987-09-25	1999-10-05	Texas Biotechnology Corporation	Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JP3050424B2 (ja) *	1991-07-12	2000-06-12	塩野義製薬株式会社	ヒトエンドセリンリセプター
US6541498B2 (en)	1993-05-20	2003-04-01	Texas Biotechnology	Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en)	1994-05-20	2002-04-23	Texas Biotechnology Corporation	Benzenesulfonamides and the use thereof to modulate the activity of endothelin
TR200202738T2 (tr) *	1997-04-28	2003-03-21	Texas Biotechnology Corporation	Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler
EP1023269A4 (en) *	1997-09-30	2001-06-27	Molecular Design Int	BETA3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF USE
CZ302691B6 (cs)	1998-07-08	2011-09-07	Sanofi - Aventis Deutschland GmbH	N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
AU2456701A (en) *	1999-12-31	2001-07-16	Texas Biotechnology Corporation	Pharmaceutical and veterinary uses of endothelin antagonists
SK9532002A3 (en)	1999-12-31	2003-06-03	Texas Biotechnology Corp	Sulfonamides and derivatives thereof that modulate the activity of endothelin
EP1533311B1 (en) *	1999-12-31	2007-04-25	Encysive Pharmaceuticals, Inc	Sulfonamides and derivatives thereof that modulate the activity of endothelin
US6593341B2 (en)	2001-03-29	2003-07-15	Molecular Design International, Inc.	β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
US8329924B2 (en) *	2001-06-11	2012-12-11	Vertex Pharmaceuticals (Canada) Incorporated	Compounds and methods for the treatment or prevention of Flavivirus infections
EP2363396A1 (en) *	2001-06-11	2011-09-07	Virochem Pharma Inc.	Thiophene derivatives as antiviral agents for flavivirus infection
DE60324104D1 (en) *	2002-01-30	2008-11-27	Amgen Inc	Arylsulfonamidobenzylverbindungen
US6596734B1 (en)	2002-10-11	2003-07-22	Molecular Design International, Inc.	Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
DE60332482D1 (de)	2002-12-10	2010-06-17	Virochem Pharma Inc	Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
US7754831B2 (en) *	2002-12-25	2010-07-13	Mitsubishi Rayon Co., Ltd.	Vinyl polymer, process for producing vinyl polymer, thermosetting coating composition, and coating material
US20060011305A1 (en) *	2003-09-19	2006-01-19	Donald Sandell	Automated seal applicator
US7871632B2 (en) *	2004-07-12	2011-01-18	Adventrx Pharmaceuticals, Inc.	Compositions for delivering highly water soluble drugs
US20060252831A1 (en) *	2005-05-06	2006-11-09	Christopher Offen	Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) *	2005-05-06	2006-11-09	Brandon Stephen F	Method for the treatment of magnesium and potassium deficiencies
AU2011205048B2 (en) *	2005-05-13	2013-05-02	Virochem Pharma Inc.	Compounds and methods for the treatment or prevention of flavivirus infections
JP5030947B2 (ja) *	2005-05-13	2012-09-19	ヴァイロケム・ファーマ・インコーポレーテッド	フラビウイルス感染の治療及び予防のための化合物及び方法
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
US20070219825A1 (en) *	2005-11-23	2007-09-20	Maetzold Derek J	Method of managing and reducing side effects associated with exposure to a drug
EP1996588A4 (en) *	2006-03-03	2011-10-05	Torrent Pharmaceuticals Ltd	NEW DUAL ACTION RECEPTOR (DARA) ANTAGONISTS OF ATI AND ETA RECEPTORS
WO2007106468A2 (en) *	2006-03-13	2007-09-20	Encysive Pharmaceuticals, Inc.	Formulations of sitaxsentan sodium
BRPI0708879A2 (pt) *	2006-03-13	2011-06-14	Encysive Pharmaceuticals	peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
US20080026061A1 (en) *	2006-06-22	2008-01-31	Reichwein John F	Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
SG176488A1 (en) *	2006-11-15	2011-12-29	Virochem Pharma Inc	Thiophene analogues for the treatment or prevention of flavivirus infections
CL2008000835A1 (es)	2007-03-23	2008-10-03	Icagen Inc Pfizer Ltd	Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
JP2009026126A (ja) *	2007-07-20	2009-02-05	Nec Electronics Corp	半導体装置
KR20100099113A (ko) *	2007-10-12	2010-09-10	아스트라제네카 아베	만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물
EP2511263A1 (en)	2011-04-14	2012-10-17	Phenex Pharmaceuticals AG	Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US10463656B2 (en)	2017-01-05	2019-11-05	Iowa State University Research Foundation, Inc.	Methods and compositions for prevention of feedlot bovine respiratory disease
CN106831736A (zh) *	2017-02-15	2017-06-13	浙江华海药业股份有限公司	一种制备帕罗西汀杂质的方法
GB201810092D0 (en)	2018-06-20	2018-08-08	Ctxt Pty Ltd	Compounds
GB201810581D0 (en)	2018-06-28	2018-08-15	Ctxt Pty Ltd	Compounds
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
SI4299135T1 (sl)	2019-06-18	2025-12-31	Pfizer Inc.	Benzizoksazolni sulfonamidni derivati
WO2022197658A1 (en) *	2021-03-15	2022-09-22	The Board Of Trustees Of The University Of Illinois	Compounds, compositions, and methods for treating type 2 diabetes and dementia
CN117255791B (zh)	2021-06-22	2026-06-19	亚克医药株式会社	化合物、内皮素a受体拮抗剂及医药组合物

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB804036A (en)	1956-03-02	1958-11-05	Hoffmann La Roche	A process for the manufacture of a sulphanilamide of the isoxazole series
US2888455A (en)	1956-09-04	1959-05-26	Shionogi & Co	New sulfonamide and process for producing the same
US3225085A (en)	1961-09-15	1965-12-21	Monsanto Co	Succinic acid derivatives
US3300488A (en)	1963-12-23	1967-01-24	Shionogi & Co	Nu, nu'-bis [4-halogenated-5-alkyl-3-isoxazolylsulfamoyl)-phenyl]-ureas
US3660383A (en)	1968-08-14	1972-05-02	Shionogi & Co	Production of iodoisoxazole compounds
US3710795A (en)	1970-09-29	1973-01-16	Alza Corp	Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en)	1972-04-20	1976-03-24	Allen & Hanburys Ltd	Physically anti-inflammatory steroids for use in aerosols
US4044126A (en)	1972-04-20	1977-08-23	Allen & Hanburys Limited	Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en)	1972-12-08	1976-05-18	Syntex (U.S.A.) Inc.	Dialkylated glycol compositions and medicament preparations containing same
GB1473433A (id)	1975-10-09	1977-05-11	Banyu Pharmaceutical Co Ltd Hi
US4315014A (en)	1980-09-24	1982-02-09	Warner-Lambert Company	Antibacterial amide compounds and pharmaceutical composition containing the same
US4410545A (en)	1981-02-13	1983-10-18	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4328245A (en)	1981-02-13	1982-05-04	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4358603A (en)	1981-04-16	1982-11-09	Syntex (U.S.A.) Inc.	Acetal stabilized prostaglandin compositions
EP0076072B1 (en)	1981-09-24	1987-05-13	BEECHAM - WUELFING GmbH & Co. KG	Sulphonamides
US4409239A (en)	1982-01-21	1983-10-11	Syntex (U.S.A.) Inc.	Propylene glycol diester solutions of PGE-type compounds
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0194548A3 (de)	1985-03-12	1988-08-17	Dr. Karl Thomae GmbH	Neue Sulfonylaminoäthylverbindungen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US4914112A (en)	1986-06-03	1990-04-03	Sumitomo Pharmaceuticals Company, Limited	Aminoazole derivatives and their production and use
DE3735555A1 (de) *	1987-03-07	1988-09-15	Bayer Ag	Aminomethylheterocyclen
NZ225307A (en) *	1987-07-10	1991-06-25	Hoffmann La Roche	Heterocyclic containing alkene derivatives and pharmaceutical compositions
US4752613A (en)	1987-08-03	1988-06-21	E. R. Squibb & Sons, Inc.	Sulphonamidothienylcarboxylic acid compounds
US5594021A (en)	1993-05-20	1997-01-14	Texas Biotechnology Corporation	Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en)	1993-05-20	1996-11-05	Texas Biotechnology Corporation	Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en)	1993-05-20	1996-05-07	Immunopharmaceutics, Inc.	N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en)	1993-05-20	1995-11-07	Immunopharmaceutics, Inc.	N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) *	1993-05-20	1997-01-07	Texas Biotechnology Corporation	Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en)	1987-09-25	1999-10-05	Texas Biotechnology Corporation	Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5112866A (en) *	1988-09-06	1992-05-12	Ortho Pharmaceutical Corporation	Ethanesulfonamide derivatives
US4997836A (en)	1988-11-11	1991-03-05	Takeda Chemical Industries, Ltd.	Trisubstituted piperazine compounds, their production and use
ES2097142T3 (es)	1989-02-10	1997-04-01	Otsuka Pharma Co Ltd	Derivados de indol, su preparacion y medicamento que los contiene destinado para la prevencion y para el tratamiento de la nefritis.
US5082838A (en)	1989-06-21	1992-01-21	Takeda Chemical Industries, Ltd.	Sulfur-containing fused pyrimidine derivatives, their production and use
JPH0347163A (ja)	1989-06-30	1991-02-28	Fujisawa Pharmaceut Co Ltd	アントラキノン誘導体およびその製造
US5230999A (en)	1989-07-24	1993-07-27	Takeda Chemical Industries, Ltd.	Monoclonal antibody to endothelin-3 or precursor thereof and use thereof
CA2032559C (en)	1989-12-28	2001-11-06	Kiyofumi Ishikawa	Endothelin antagonistic cyclic pentapeptides
US5284828A (en)	1990-05-14	1994-02-08	Fujisawa Pharmaceutical Co. Ltd.	Peptide compound and its preparation
CA2043741C (en)	1990-06-07	2003-04-01	Kiyofumi Ishikawa	Endothelin antagonistic peptide derivatives
CA2056142A1 (en)	1990-11-27	1992-05-28	Hirotomo Masuya	Pyridopyridazine compounds and their use
CA2059380A1 (en)	1991-01-24	1992-07-25	Yiu-Kuen T. Lam	Endothelin receptor antagonists isolated from microbispora
US5248807A (en)	1991-01-29	1993-09-28	Shionogi & Co., Ltd.	Triterpene derivatives
US5352659A (en)	1991-02-15	1994-10-04	Takeda Chemical Industries	Endothelin analogs and uses thereof
TW270116B (id)	1991-04-25	1996-02-11	Hoffmann La Roche
US5382569A (en)	1991-05-16	1995-01-17	Warner-Lambert Company	Endotherlin antagonists
RU2086544C1 (ru)	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
FR2679906B1 (fr)	1991-07-31	1995-01-20	Adir	Nouvelles (isoquinolein-5 yl) sulfonamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB2259450A (en)	1991-09-11	1993-03-17	Fujisawa Pharmaceutical Co	Compositions with endothelin antagonist activity
US5198548A (en)	1992-01-30	1993-03-30	Warner-Lambert Company	Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof
FR2687675B1 (fr)	1992-01-31	1997-04-18	Roussel Uclaf	Nouveaux derives bicycliques de la pyridine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
TW224462B (id)	1992-02-24	1994-06-01	Squibb & Sons Inc
US5378715A (en)	1992-02-24	1995-01-03	Bristol-Myers Squibb Co.	Sulfonamide endothelin antagonists
LT3200B (en)	1992-03-18	1995-03-27	Takeda Chemical Industries Ltd	Triazolopyridazine methodfor production thereof and use
US5240910A (en)	1992-04-17	1993-08-31	Merck & Co., Inc.	Antihypertensive compounds produced by fermentation
NZ247440A (en) *	1992-05-06	1995-04-27	Squibb & Sons Inc	Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5514696A (en)	1992-05-06	1996-05-07	Bristol-Myers Squibb Co.	Phenyl sulfonamide endothelin antagonists
AU4376893A (en)	1992-05-19	1993-12-13	Immunopharmaceutics, Inc.	Compounds that modulate endothelin activity
ES2042421B1 (es)	1992-05-22	1994-08-01	Uriach & Cia Sa J	Procedimiento para la obtencion de la 8-cloro-11-1-(5-metil-3-piridil)metil-4-piperidiliden-6,11-dihidro-5h-benzo5,6ciclohepta1,2-bpiridina.
US5783701A (en)	1992-09-08	1998-07-21	Vertex Pharmaceuticals, Incorporated	Sulfonamide inhibitors of aspartyl protease
IS2334B (is)	1992-09-08	2008-02-15	Vertex Pharmaceuticals Inc., (A Massachusetts Corporation)	Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
TW287160B (id)	1992-12-10	1996-10-01	Hoffmann La Roche
US5420123A (en)	1992-12-21	1995-05-30	Bristol-Myers Squibb Company	Dibenzodiazepine endothelin antagonists
US5352800A (en)	1993-03-11	1994-10-04	Merck & Co., Inc.	Process for the production of a novel endothelin antagonist
US5565485A (en)	1993-03-19	1996-10-15	Merck & Co., Inc.	Biphenyl compounds useful or endothelin antagonists
US5420133A (en)	1993-03-19	1995-05-30	Merck & Co., Inc.	Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5334598A (en)	1993-03-19	1994-08-02	Merck & Co., Inc.	Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
ES2062943B1 (es)	1993-03-23	1995-11-16	Uriach & Cia Sa J	Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
FI941826L (fi)	1993-04-21	1994-10-22	Takeda Chemical Industries Ltd	Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US6030991A (en)	1993-05-20	2000-02-29	Texas Biotechnology Corp.	Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en)	1993-05-20	2002-01-29	Texas Biotechnology Corp.	N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
FR2707089B1 (fr)	1993-06-30	1995-08-18	Adir	Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5389620A (en)	1993-08-18	1995-02-14	Banyu Pharmaceutical Co., Ltd.	Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
JPH09501920A (ja)	1993-08-19	1997-02-25	ワーナー−ランバート・コンパニー	非ペプチドエンドセリンアンタゴニスト▲ｉ▼
US5965732A (en)	1993-08-30	1999-10-12	Bristol-Myers Squibb Co.	Sulfonamide endothelin antagonists
US5661152A (en)	1993-10-15	1997-08-26	Schering Corporation	Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6063911A (en)	1993-12-01	2000-05-16	Marine Polymer Technologies, Inc.	Methods and compositions for treatment of cell proliferative disorders
IL111959A (en)	1993-12-17	2000-07-16	Tanabe Seiyaku Co	N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
JP3328045B2 (ja)	1994-02-08	2002-09-24	日清製粉株式会社	粉体サンプル調整装置
GB9504854D0 (en)	1994-03-31	1995-04-26	Zeneca Ltd	Nitrogen derivatives
GB9409618D0 (en)	1994-05-13	1994-07-06	Zeneca Ltd	Pyridine derivatives
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
DE4440066A1 (de)	1994-11-10	1996-05-15	Basf Ag	Methin- und Azamethinfarbstoffe auf Basis von Trifluormethylpyridonen
NZ297774A (en)	1994-12-20	1998-10-28	Hoffmann La Roche	Aryl and heteroaryl sulphonamide derivatives; preparation and medicaments
IL116916A (en)	1995-02-06	2000-09-28	Bristol Myers Squibb Co	Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same
US5599811A (en)	1995-02-21	1997-02-04	Warner-Lambert Company	Benzothiazine dioxides as endothelin antagonists
DE19509950A1 (de)	1995-03-18	1996-09-19	Merck Patent Gmbh	Endothelin-Rezeptor-Antagonisten
EP0819125B1 (en) *	1995-04-04	2003-06-18	Texas Biotechnology Corporation	Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
UA58494C2 (uk)	1995-06-07	2003-08-15	Зенека Лімітед	Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en)	1995-06-22	1995-08-23	Zeneca Ltd	Heterocyclic compounds
US5922759A (en)	1996-06-21	1999-07-13	Warner-Lambert Company	Butenolide endothelin antagonists
US5846990A (en)	1995-07-24	1998-12-08	Bristol-Myers Squibb Co.	Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja)	1995-10-11	1997-05-13	Bristol Myers Squibb Co	置換ビフェニルスルホンアミドエンドセリン拮抗剤
SK282833B6 (sk) *	1995-11-17	2002-12-03	Warner-Lambert Company	Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
KR100456650B1 (ko)	1995-12-20	2005-06-20	야마노우치세이야쿠 가부시키가이샤	아릴에텐설폰아미드유도체
US5977117A (en)	1996-01-05	1999-11-02	Texas Biotechnology Corporation	Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
NZ331941A (en) *	1996-02-22	2000-04-28	Tularik Inc	Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis
US5958905A (en)	1996-03-26	1999-09-28	Texas Biotechnology Corporation	Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
AU2529297A (en)	1996-04-10	1997-10-29	Warner-Lambert Company	Ketoacid endothelin antagonists
US6133263A (en)	1996-04-10	2000-10-17	Warner-Lambert Company	Endothelin antagonists with ether-linked groups
US5804585A (en)	1996-04-15	1998-09-08	Texas Biotechnology Corporation	Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9702194D0 (en) *	1997-02-04	1997-03-26	Lilly Co Eli	Sulphonide derivatives
TR200202738T2 (tr) *	1997-04-28	2003-03-21	Texas Biotechnology Corporation	Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler
US5783705A (en)	1997-04-28	1998-07-21	Texas Biotechnology Corporation	Process of preparing alkali metal salys of hydrophobic sulfonamides
US6313119B1 (en) *	1998-01-23	2001-11-06	Adventis Pharma Deutschland Gmbh	Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6300341B1 (en) *	1998-09-30	2001-10-09	The Procter & Gamble Co.	2-substituted heterocyclic sulfonamides
US6313123B1 (en) *	1999-01-27	2001-11-06	American Cyanamid Company	Acetylenic sulfonamide thiol tace inhibitors
SK9532002A3 (en)	1999-12-31	2003-06-03	Texas Biotechnology Corp	Sulfonamides and derivatives thereof that modulate the activity of endothelin

1998
- 1998-04-02 TR TR2002/02738T patent/TR200202738T2/xx unknown
- 1998-04-02 EE EEP199900469A patent/EE04156B1/xx not_active IP Right Cessation
- 1998-04-02 DE DE69839534T patent/DE69839534D1/de not_active Expired - Lifetime
- 1998-04-02 PL PL336290A patent/PL197843B1/pl not_active IP Right Cessation
- 1998-04-02 ID IDW991119A patent/ID25921A/id unknown
- 1998-04-02 IL IL15697798A patent/IL156977A/xx not_active IP Right Cessation
- 1998-04-02 NZ NZ336898A patent/NZ336898A/en unknown
- 1998-04-02 AU AU69504/98A patent/AU749167B2/en not_active Ceased
- 1998-04-02 HU HU0001442A patent/HU227183B1/hu not_active IP Right Cessation
- 1998-04-02 US US09/403,599 patent/US6432994B1/en not_active Expired - Lifetime
- 1998-04-02 CZ CZ0367599A patent/CZ301452B6/cs not_active IP Right Cessation
- 1998-04-02 CN CNB988046148A patent/CN1179961C/zh not_active Expired - Fee Related
- 1998-04-02 CN CN2004100923126A patent/CN1636994B/zh not_active Expired - Fee Related
- 1998-04-02 SK SK1433-99A patent/SK143399A3/sk unknown
- 1998-04-02 DE DE69829558T patent/DE69829558T2/de not_active Expired - Lifetime
- 1998-04-02 CA CA002496680A patent/CA2496680A1/en not_active Abandoned
- 1998-04-02 JP JP54098298A patent/JP3455233B2/ja not_active Expired - Fee Related
- 1998-04-02 TR TR2001/01905T patent/TR200101905T2/xx unknown
- 1998-04-02 ES ES98915281T patent/ES2241133T3/es not_active Expired - Lifetime
- 1998-04-02 AP APAP/P/1999/001643A patent/AP9901643A0/en unknown
- 1998-04-02 CA CA002281090A patent/CA2281090C/en not_active Expired - Fee Related
- 1998-04-02 WO PCT/US1998/006680 patent/WO1998049162A1/en not_active Ceased
- 1998-04-02 EA EA199900966A patent/EA003993B1/ru not_active IP Right Cessation
- 1998-04-02 EP EP98915281A patent/EP0980369B1/en not_active Expired - Lifetime
- 1998-04-02 TR TR1999/02401T patent/TR199902401T2/xx unknown
- 1998-04-02 AT AT98915281T patent/ATE292129T1/de not_active IP Right Cessation
- 1998-04-02 SG SG200106590A patent/SG100766A1/en unknown
- 1998-04-02 BR BR9812258-4A patent/BR9812258A/pt not_active Application Discontinuation
- 1998-04-02 IL IL13131898A patent/IL131318A/en not_active IP Right Cessation
- 1998-04-02 SG SG200106591A patent/SG100767A1/en unknown
1999
- 1999-10-22 OA OA9900233A patent/OA11167A/en unknown
- 1999-10-26 NO NO995221A patent/NO995221L/no unknown
2001
- 2001-02-23 US US09/792,237 patent/US6458805B2/en not_active Expired - Fee Related
- 2001-12-20 US US10/029,561 patent/US6683103B2/en not_active Expired - Fee Related
2002
- 2002-12-04 JP JP2002352236A patent/JP4256150B2/ja not_active Expired - Fee Related
2007
- 2007-12-12 JP JP2007320895A patent/JP2008074875A/ja active Pending

Also Published As

Publication number	Publication date
US20010039289A1 (en)	2001-11-08
CA2281090C (en)	2005-06-07
IL131318A (en)	2004-08-31
EP0980369A1 (en)	2000-02-23
DE69829558D1 (de)	2005-05-04
PL197843B1 (pl)	2008-05-30
AU749167B2 (en)	2002-06-20
JP2003176288A (ja)	2003-06-24
ES2241133T3 (es)	2005-10-16
JP2008074875A (ja)	2008-04-03
AP9901643A0 (en)	1999-10-02
CN1253560A (zh)	2000-05-17
DE69839534D1 (de)	2008-07-03
WO1998049162A1 (en)	1998-11-05
CA2496680A1 (en)	1998-11-05
US6683103B2 (en)	2004-01-27
TR199902401T2 (xx)	2000-08-21
CZ301452B6 (cs)	2010-03-10
JP2001520643A (ja)	2001-10-30
TR200202738T2 (tr)	2003-03-21
IL156977A0 (en)	2004-02-08
CZ367599A3 (cs)	2000-02-16
AU6950498A (en)	1998-11-24
HK1028033A1 (en)	2001-03-02
JP3455233B2 (ja)	2003-10-14
NZ336898A (en)	2001-10-26
US20020091270A1 (en)	2002-07-11
TR200101905T2 (tr)	2002-06-21
BR9812258A (pt)	2000-07-25
CN1636994A (zh)	2005-07-13
CN1179961C (zh)	2004-12-15
SG100767A1 (en)	2003-12-26
ID25921A (id)	2000-11-09
ATE292129T1 (de)	2005-04-15
HUP0001442A3 (en)	2001-12-28
NO995221D0 (no)	1999-10-26
SK143399A3 (en)	2000-05-16
DE69829558T2 (de)	2006-02-16
EP0980369B1 (en)	2005-03-30
CA2281090A1 (en)	1998-11-05
EE9900469A (et)	2000-06-15
SG100766A1 (en)	2003-12-26
JP4256150B2 (ja)	2009-04-22
US6432994B1 (en)	2002-08-13
PL336290A1 (en)	2000-06-19
IL156977A (en)	2005-03-20
OA11167A (en)	2003-04-29
HU227183B1 (en)	2010-09-28
HUP0001442A2 (hu)	2001-11-28
CN1636994B (zh)	2010-05-12
EA199900966A1 (ru)	2000-08-28
EA003993B1 (ru)	2003-12-25
US6458805B2 (en)	2002-10-01
EE04156B1 (et)	2003-10-15
IL131318A0 (en)	2001-01-28

Publication	Publication Date	Title
AP9901643A0 (en)	1999-10-02	Sulfonamides for treatment of endothelin-mediated disorders.
Murcia-Soler et al.	2004	Artificial neural networks and linear discriminant analysis: a valuable combination in the selection of new antibacterial compounds
DE69012318D1 (de)	1994-10-13	Impfstoffe gegen hämophilus influenzae.
NO20092714L (no)	2004-10-11	Fremgangsmate ved induksjon av terminal differensiering
NO20003332L (no)	2000-08-18	Midisinforløper av aspartylproteaseinhibitorer
NO20044795L (no)	2004-11-04	Forbindelser som modulerer PPAR aktivitet og fremgangsmater for deres fremstilling
EP1944300A3 (en)	2008-11-05	Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
DE60321318D1 (de)	2008-07-10	Gewinnung von delta-9 tetrahydrocannabinol
HUP0101999A2 (hu)	2001-11-28	4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
DK0896533T3 (da)	2004-01-26	Pentafluorbenzensulfonamider og analoger
ATE221527T1 (de)	2002-08-15	Als carbohydrase-inhibitoren verwendbare thiophen sulfonamide
NO20053846L (no)	2005-08-16	Fremgangsmate for a modifisere legemiddel-krystalldannelse
DK254787D0 (da)	1987-05-19	Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel
KR950031060A (ko)	1995-12-18	골다공증 치료용 약제학적 조성물
ATE493978T1 (de)	2011-01-15	Behandlung von autoimmunerkrankungen
DE69333723D1 (de)	2005-01-20	Pharmazeutische zubereitung auf der basis von rhamnolipid gegen dermatologische erkrankungen
DE69834500D1 (de)	2006-06-14	Xanthinderivative zur behandlung von hirnischämie
SE8005773L (sv)	1981-02-17	Enterala overdragna fasta farmaceutiska enhetsdosformer
BR0011728A (pt)	2002-02-26	Método de inibir a agregação de proteìna amilóide e imagem de depósitos de amilóide
ATE357212T1 (de)	2007-04-15	Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin
EA200401090A1 (ru)	2005-02-24	Композиция на основе диклофенака для местного лечения заболеваний орофарингеальной полости
RU2003104017A (ru)	2004-08-20	Ингибиторы тромбина, содержащие аминоизохинолиновую группу
DK1064262T3 (da)	2003-05-12	Substituerede isoindoloner og deres anvendelse som cycliske GMP-modulatorer i lægemidler
ATE410164T1 (de)	2008-10-15	Wässrige flüssige preparation von pranoprofen
RU2006114352A (ru)	2006-08-27	Производные бициклических иминокислот в качестве ингибиторов матриксных металлопротеиназ